ລັດຄາລິຟໍເນຍໄດ້ຟ້ອງຮ້ອງ Eli Lilly ແລະຜູ້ຜະລິດອິນຊູລິນອື່ນໆສໍາລັບການຂັບລົດຄ່າຢາ

ໄດ້ ກົດຫມາຍວ່າດ້ວຍ, filed Thursday in Los Angeles Superior Court, also lists drug makers Novo Nordisk and Sanofi, as well as pharmacy benefit management companies CVS Caremark, Express Scripts and OptumRx, according to a ປະຊາສໍາພັນ from Bonta’s office.

The complaint alleges the insulin makers—which produce more than 90% of the global supply of insulin—as well as the pharmacy benefit management companies that control the drugs covered on health insurance plans, have “leveraged their market power” in an effort to overcharge diabetes patients.

Bonta accused those companies of violating the state’s Unfair Competition Law by “unacceptably and artificially” inflating insulin costs, making it so expensive that “many diabetics struggle to afford it” even if it’s covered by their health insurance.

The suit specifically accuses the drug makers of “aggressively” increasing the list price of insulin “in lockstep with each other,” hurting both diabetes patients and competition.

It also claims pharmacy benefit managers are incentivized to boost the cost of insulin due to a system of “secret” rebates they receive from drugmakers in return for preferable placement in the management companies’ health insurance programs—those rebates are based on the list price of insulin.

Eli Lilly and CVS Caremark both denied the allegations in statement to Forbes, with Eli Lilly arguing the lawsuit “ignores that anyone is eligible to purchase their monthly prescription of Lilly insulin for $35 or less” and CVS Caremark saying “nothing in our agreements” prevents drug makers from lowering insulin prices.

Novo Nordisk refused to comment on the suit, while the other three defendants did not immediately respond to a Forbes inquiry for comment.